Clinic
Knapp Medical Center
Knapp Medical Center was paid $6.62M by Medicaid between Mar 2019 and Dec 2024, across 96 billing codes. Its largest line is 99285, emergency room visit (most serious) — 34% of everything it billed.
33Billing provider infoKNAPP MEDICAL CENTER
WESLACO, TX 78596
WESLACO, TX 78596
33aNPI1861488579assigned 09/27/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$6.62M
24GClaims162,626
24DCodes billed96
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#66 of 320
Median peer was paid$205K
This provider vs. median32×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 199 | $4K | |
| 2020 | 2,440 | $100K | |
| 2021 | 33,970 | $1.01M | |
| 2022 | 48,342 | $1.87M | |
| 2023 | 53,210 | $2.55M | |
| 2024incomplete | 24,465 | $1.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 34% | 9,266 | 8,030 | $2.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 6,988 | 6,400 | $1.43M |
| G0378 | Hospital observation service, per hour | 7.5% | 2,467 | 1,426 | $498K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.8% | 7,473 | 6,725 | $320K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.2% | 6,372 | 6,066 | $280K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.1% | 2,794 | 2,547 | $206K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.3% | 5,694 | 2,783 | $152K |
| 80053 | Comprehensive metabolic panel | 1.9% | 11,333 | 9,573 | $123K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 15,247 | 12,365 | $117K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 5,371 | 4,846 | $115K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 3,650 | 3,310 | $108K |
| 59025 | Fetal non-stress test | 1.4% | 1,202 | 993 | $95K |
84 more codes
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 121 | $79K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.0% | 2,530 | $68K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 3,594 | $67K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,000 | $64K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 229 | $48K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,800 | $42K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 794 | $42K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,063 | $40K |
| 83690 | <1% | 5,192 | $38K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 232 | $34K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,582 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,678 | $27K |
| 76801 | <1% | 243 | $27K | |
| 81001 | <1% | 7,391 | $26K | |
| 87081 | <1% | 2,116 | $23K | |
| 84702 | <1% | 1,242 | $19K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 234 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,364 | $14K |
| 87040 | <1% | 1,909 | $14K | |
| 86140 | <1% | 2,121 | $13K | |
| 83880 | <1% | 982 | $12K | |
| 84484 | <1% | 2,133 | $11K | |
| 83605 | <1% | 1,473 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,781 | $10K |
| 87420 | <1% | 353 | $9K | |
| 84703 | <1% | 806 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,795 | $9K |
| 81025 | <1% | 672 | $8K | |
| 81003 | <1% | 3,120 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 202 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 210 | $7K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 46 | $7K |
| 87581 | <1% | 98 | $6K | |
| 87486 | <1% | 98 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 574 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 939 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,787 | $4K |
| 82550 | <1% | 1,050 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 92 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 15 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,296 | $3K |
| 85730 | <1% | 1,410 | $3K | |
| 85610 | <1% | 1,728 | $3K | |
| 86850 | <1% | 690 | $3K | |
| 87077 | <1% | 831 | $3K | |
| 87186 | <1% | 767 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,176 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,747 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,612 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,256 | $2K |
| 80061 | Lipid panel | <1% | 460 | $2K |
| J3490 | Unclassified drugs | <1% | 612 | $2K |
| 86900 | <1% | 918 | $2K | |
| 86901 | <1% | 917 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 381 | $1K |
| 83735 | <1% | 515 | $1K | |
| 74018 | <1% | 31 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $1K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $972.30 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $952.46 |
| 80320 | <1% | 59 | $787.24 | |
| CP007 | <1% | 29 | $683.09 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 400 | $628.38 |
| 83525 | <1% | 27 | $558.29 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 20 | $448.32 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 40 | $372.65 |
| 82947 | <1% | 220 | $321.12 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 97 | $242.62 |
| 82805 | <1% | 15 | $191.89 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 198 | $175.96 |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 140 | $124.69 |
| 87070 | <1% | 19 | $71.32 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,449 | $58.61 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19 | $51.88 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 12 | $16.32 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 238 | $12.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 21 | $5.28 |
| 82962 | <1% | 2,515 | $4.70 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 44 | $2.02 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 42 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 50 | $0.00 |
| 82570 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSURROCK, LESTER (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Mission Hospital, INC. | Mission, TX | $7.84M |
| Mission Hospital INC | Mission, TX | $106K |
| Mission Doctors Group | Mission, TX | $69K |
| Knapp Medical Group | Weslaco, TX | $59K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.